School of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand;Translational Medicine Programs, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand.
Turk J Gastroenterol. 2021 Mar;32(3):261-268. doi: 10.5152/tjg.2021.20108.
The LGR5 and CD133 have been identified as cancer stem cells (CSCs) marker and prognostic marker in several cancers including gastric cancer. The purpose of the present study was to determine the association between co-expression of CSCs marker LGR5 and CD133 in patients with gastric cancer and their clinicopathological outcomes; to analyze the efficacy of co-expression of both markers in evaluating the prognosis of gastric cancer.
LGR5 and CD133 expression were investigated in a total of 400 patients by using immunohistochemistry. Results were analyzed in association with patient characteristics outcomes. Overall survival was performed using Kaplan-Meier Curve analysis.
LGR5 and CD133 were found positive in 219/400 (54.75%) and 251/400 (62.75%) respectively in gastric cancer tissues. Co-expression of LGR5 and CD 133 were significantly associated with poor clinicopathological outcomes, including lymphatic invasion, vascular invasion, higher pathological T stage, and higher TNM staging (stage IV) (P < .05). The overall survival of patients who were positive for LGR5 and CD133 had shorter than that of LGR5 and CD133-negative gastric cancer, especially in patients who were positive for both markers.
Our finding indicates that co-expression of LGR5 and CD133 could be used as a marker indicating poor prognosis, which can provide information for selected effective treatment and carried out of intensive follow-up in gastric cancer patients.
LGR5 和 CD133 已被确定为包括胃癌在内的几种癌症中的癌症干细胞 (CSC) 标志物和预后标志物。本研究的目的是确定胃癌患者中 LGR5 和 CD133 这两种 CSC 标志物的共表达与临床病理结局之间的关系；分析这两个标志物的共表达在评估胃癌预后中的效果。
通过免疫组织化学法共检测了 400 例患者中 LGR5 和 CD133 的表达。结果与患者的特征和结局进行了分析。采用 Kaplan-Meier 曲线分析进行总生存分析。
在 400 例胃癌组织中，LGR5 和 CD133 的阳性率分别为 219/400（54.75%）和 251/400（62.75%）。LGR5 和 CD133 的共表达与较差的临床病理结局显著相关，包括淋巴血管侵犯、较高的病理 T 分期和较高的 TNM 分期（IV 期）（P<.05）。LGR5 和 CD133 阳性的患者总生存时间短于 LGR5 和 CD133 阴性的胃癌患者，尤其是在这两个标志物均阳性的患者中。
我们的研究结果表明，LGR5 和 CD133 的共表达可作为预后不良的标志物，为胃癌患者提供了选择有效治疗和进行强化随访的信息。
